Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases

British Journal of Cancer

Volumn 112, Issue 2, 2015, Pages 345-351

  Horimoto, Y ^a   Arakawa, A ^a   Harada Shoji, N ^b   Sonoue, H ^a   Yoshida, Y ^a   Himuro, T ^a   Igari, F ^a   Tokuda, E ^a   Mamat, O ^a   Tanabe, M ^a   Hino, O ^a   Saito, M ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

FOXA1; Luminal breast cancer; Neo adjuvant chemotherapy; Pathological complete response

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR; UVOMORULIN; VIMENTIN; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; ERBB2 PROTEIN, HUMAN; FOXA1 PROTEIN, HUMAN; TAXANE; TAXOID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST BIOPSY; BREAST CANCER; BREAST CANCER CELL LINE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE FREE SURVIVAL; DRUG EFFICACY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE SILENCING; HER2 NEGATIVE BREAST CANCER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; WESTERN BLOTTING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; TUMOR CELL LINE; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922337369     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.595     Document Type: Article

References (28)

1. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H (2007) FOXA1 expression in breast cancer- correlation with luminal subtype A and survival. Clin Cancer Res 13: 4415-4421.
2. Bernardo GM, Bebek G, Ginther CL, Sizemore ST, Lozada KL, Miedler JD, Anderson LA, Godwin AK, Abdul-Karim FW, Slamon DJ, Keri RA (2013) FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene 32: 554-563.
3. Denkert C, Loibl S, Müller BM, Eidtmann H, Schmitt WD, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Erbstößer E, Blohmer JU, Budczies J, Mehta KM, Von Minckwitz G (2013) Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol 24: 2786-2793.
4. Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, Rauh C, Schulz-Wendtland R, Bani MR, Schrauder M, Kahmann L, Lux MP, Strehl JD, Hartmann A, Dimmler A, Beckmann MW, Wachter DL (2011) Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 11: 486.
5. Fu X, Huang C, Schiff R (2011) More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response. Breast Cancer Res 13: 307.
6. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn H-J (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24: 2206-2223.
7. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn H-J (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133-1144.
8. Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO (2008) Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer 44: 1541-1551.
9. Hisamatsu Y, Tokunaga E, Yamashita N, Akiyoshi S, Okada S, Nakashima Y, Aishima S, Morita M, Kakeji Y, Maehara Y (2012) Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer. Ann Surg Oncol 19: 1145-1152.
10. Ho K-K, Mcguire VA, Koo C-Y, Muir KW, De Olano N, Maifoshie E, Kelly DJ, Mcgovern UB, Monteiro LJ, Gomes AR, Nebreda AR, Campbell DG, Arthur JSC, Lam EW-F (2012) Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin. J Biol Chem 287: 1545-1555.
11. Ho K-K, Rosivatz E, Gunn RM, Smith MEB, Stavropoulou AV, Rosivatz E, Numbere MG, Wong JB, Lafitte VGH, Behrendt JM, Myatt SS, Hailes HC, Woscholski R, Lam EWF (2009) The novel molecule 2-[5-(2-chloroethyl)-2-acetoxy-benzyl]-4-(2-chloroethyl)-phenyl acetate inhibits phosphoinositide 3-kinase/Akt/mammalian target of rapamycin signalling through JNK activation in cancer cells. FEBS J 276: 4037-4050.
12. Ho KK, Myatt SS, Lam EWF (2008) Many forks in the path: cycling with FoxO. Oncogene 27: 2300-2311.
13. Horimoto Y, Arakawa A, Tanabe M, Sonoue H, Igari F, Senuma K, Tokuda E, Shimizu H, Kosaka T, Saito M (2014) Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer. BMC Cancer 14: 550.
14. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS (2011) FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 43: 27-33.
15. Kawase M, Toyama T, Takahashi S, Sato S, Yoshimoto N, Endo Y, Asano T, Kobayashi S, Fujii Y, Yamashita H (2013) FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer. Breast Cancer; e-pub ahead of print 16 June 2013; doi:10.1007/s12282-013-0482-2.
16. Liu Y-N, Lee W-W, Wang C-Y, Chao T-H, Chen Y, Chen JH (2005) Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene 24: 8277-8290.
17. Peck B, Ferber EC, Schulze A (2013) Antagonism between FOXO and Myc regulates cellular powerhouse. Front Oncol 3: 96.
18. Peppercorn J, Perou CM, Carey LA (2008) Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 26: 1-10.
19. Robinson J, Carroll J (2012) FoxA1 is a key mediator of hormonal response in breast and prostate cancer. Front Endocrinol 3: 68.
20. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin S-F, Palmieri C, Caldas C, Carroll JS (2012) Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481: 389-393.
21. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale A-L, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci 100: 8418-8423.
22. Sasahara M, Matsui A, Ichimura Y, Hirakata Y, Murata Y, Marui E (2014) Overexpression of androgen receptor and Forkhead-box A1 protein in apocrine breast carcinoma. Anticancer Res 34: 1261-1267.
23. Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW, Cuzick J (2013) Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst 105: 1504-1511.
24. Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S (2008) Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J Clin Pathol 61: 327-332.
25. Tominaga N, Naoi Y, Shimazu K, Nakayama T, Maruyama N, Shimomura A, Kim SJ, Tamaki Y, Noguchi S (2012) Clinicopathological analysis of GATA3-positive breast cancers with special reference to response to neoadjuvant chemotherapy. Ann Oncol 23: 3051-3057.
26. VonMinckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30: 1796-1804.
27. Williamson EA, Wolf I, O'kelly J, Bose S, Tanosaki S, Koeffler HP (2005) BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27Kip1. Oncogene 25: 1391-1399.
28. Wolf I, Bose S, Williamson EA, Miller CW, Karlan BY, Koeffler HP (2007) FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer 120: 1013-1022.